Latest

ORIGINS AND TIMELINE OF THE REDUCING BUREAUCRACY IN CLINICAL TRIALS INITIATIVE

December 2021-February 2022

  • Dissemination of the Coalition Recommendations. Additional endorsements are received from medical and patient associations as well as from clinical research collaborative groups and initiatives such as HOVON, TranspariMED and ECOG-ACRIN.
  • Publication of a summary of the Coalition Recommendations by and for patients (link).
  • The EU Clinical Trials Regulation comes into effect on January 31, 2022. The Coalition Recommendations are welcomed by the European Commission and used for updating the CTR Q&A (see ‘Resources’).
  • In January, the Accelerating Clinical Trials in the EU (ACT EU) initiative is announced by the European Commission (EC), the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA). ACT EU is foreseen as platform for collaborative action by regulators and stakeholders – including the Coalition – aimed at transforming how clinical trials are designed and conducted in the EU. Several Coalition priorities are among its objectives: reducing administrative burdens, patient-centricity, increased support for academic investigators, and better integration of ethics committees in the clinical trials lifecycle.

 

March-May 2022

  • Presentation of the Coalition’s work at a joint meeting of the EMA working parties for Health Care Professionals and Patients & Consumers.
  • The Coalition Recommendations are discussed at meetings of the Cancer Medicines Forum, the BioMed Alliance and EFPIA.
  • Scoping of potential follow-up actions to promote awareness and uptake of the Coalition Recommendations in conversations with various stakeholders.

 

June-November 2021

  • Elaboration of Coalition Recommendations, taking into account feedback from stakeholders collected during the Roundtable meetings and informal consultations

 

August-September 2021

 

April-May 2021

  • Multistakeholder roundtables on Regulatory Guidelines (30 April), Informed Consent (3 May) and Safety Reporting (17 May). Regulators, the European Commission, industry, ethics committees, academic clinical research organisers and the Good Clinical Trials Collaborative are invited to comment on the draft Coalition Recommendations and share their own views and concerns.

 

November 2020-March 2021

  • Drafting of Coalition Recommendations
  • Informal consultation with stakeholders
  • Alignment with the Good Clinical Trials Collaborative and the ICH E6 revision process

 

September-October 2020

  • Launch of Coalition Statement Reducing bureaucracy in clinical trials: now is the time!
  • Coalition meeting, formation of working groups tasked with formulating Coalition recommendations

 

Spring-summer 2020

  • The emerging coalition of medical societies and patient advocates, coordinated by EHA in close conjunction with the BioMed Alliance, begins drafting a joint statement to raise awareness of bureaucratic obstacles in clinical research and to call for collaborative multi-stakeholder action to address them.
  • Various coalition members take part in the ICH E6(R3) Good Clinical Practice workshop through the EMA Working Parties for patients and consumers (PCWP) and healthcare professionals (HCPWP).

 

March-April 2020

  • Publication of Reducing Bureaucracy in clinical research: a Call for Action in HemaSphere (Gribben et al., April 2020)
  • Cross-disciplinary meeting on bureaucracy in clinical research hosted by EHA

 

2019

  • EHA facilitates a dialogue between a group of clinical researchers in hematology and the European Medicines Agency, soon involving patient advocates and other stakeholders, around the issues raised by Professors Simon Rule and Steven Le Gouill in their article Bureaucracy is strangling clinical research, published in the British Medical Journal in March 2019.
  • Public Meeting on ICH E8(R1) – General Considerations for Clinical Studies. During this meeting in Silver Spring (USA) it is clear that representatives from European medical societies (EHA, ESMO, ESC) and patient advocates have similar concerns about increasing administrative pressures on investigators and participants in clinical trials.

Share this: